$NVFY
Nova Lifestyle, Inc. Stock $nvfy

$nvfy Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224019874 Filed on May 15, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$2.376M	$1.875M
YoY Change	26.77%	-48.87%
Cost Of Revenue	$1.360M	$1.213M
YoY Change	12.11%	-43.24%
Gross Profit	$1.016M	$661.3K
YoY Change	53.66%	-56.73%
Gross Profit Margin	42.76%	35.28%
Selling, General & Admin	$1.753M	$1.845M
YoY Change	-4.96%	-21.43%
% of Gross Profit	172.55%	278.98%
Research & Development	$751.2K	$118.00
YoY Change	636523.73%	-98.64%
% of Gross Profit	73.93%	0.02%
Depreciation & Amortization	$13.52K	$18.42K
YoY Change	-26.62%	-15.75%
% of Gross Profit	1.33%	2.79%
Operating Expenses	$2.505M	$1.845M
YoY Change	35.75%	-21.72%
Operating Profit	-$1.488M	-$1.184M
YoY Change	25.75%	42.88%
Interest Expense	$24.06K	-$40.43K
YoY Change	-159.51%	22.22%
% of Operating Profit
Other Income/Expense, Net	$25.64K	-$38.71K
YoY Change	-166.23%	-18.6%
Pretax Income	-$1.463M	-$1.222M
YoY Change	19.67%	36.11%
Income Tax
% Of Pretax Income
Net Earnings	-$1.463M	-$1.222M
YoY Change	19.67%	36.11%
Net Earnings / Revenue	-61.55%	-65.21%
Basic Earnings Per Share	-$0.65	-$0.17
Diluted Earnings Per Share	-$0.65	-$0.17
COMMON SHARES
Basic Shares Outstanding	2.237M shares	7.170M shares
Diluted Shares Outstanding	2.237M shares	1.434M shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$273.1K	$649.4K
YoY Change	-57.95%	-87.9%
Cash & Equivalents	$270.0K	$649.4K
Short-Term Investments
Other Short-Term Assets	$948.1K	$1.936M
YoY Change	-51.04%	214.57%
Inventory	$2.513M	$4.165M
Prepaid Expenses	$898.6K	$1.874M
Receivables	$135.9K	$262.6K
Other Receivables	$24.18K	$34.86K
Total Short-Term Assets	$3.894M	$7.049M
YoY Change	-44.76%	-72.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$267.3K	$349.4K
YoY Change	-23.5%	-89.78%
Goodwill	$218.6K	$218.6K
YoY Change	0.0%
Intangibles	$7.132K	$12.50K
YoY Change	-42.93%
Long-Term Investments
YoY Change
Other Assets	$69.24K	$71.07K
YoY Change	-2.57%	-1.92%
Total Long-Term Assets	$2.286M	$3.118M
YoY Change	-26.69%	-15.92%
TOTAL ASSETS
Total Short-Term Assets	$3.894M	$7.049M
Total Long-Term Assets	$2.286M	$3.118M
Total Assets	$6.180M	$10.17M
YoY Change	-39.22%	-64.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$572.2K	$416.2K
YoY Change	37.49%	-38.96%
Accrued Expenses	$916.1K	$1.033M
YoY Change	-11.28%	-15.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$201.9K
YoY Change
Total Short-Term Liabilities	$4.335M	$1.641M
YoY Change	164.23%	-28.3%
LONG-TERM LIABILITIES
Long-Term Debt	$146.6K	$149.8K
YoY Change	-2.14%	-0.12%
Other Long-Term Liabilities	$1.741M	$2.944M
YoY Change	-40.89%	-25.36%
Total Long-Term Liabilities	$1.887M	$3.094M
YoY Change	-39.01%	-24.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.335M	$1.641M
Total Long-Term Liabilities	$1.887M	$3.094M
Total Liabilities	$6.223M	$4.735M
YoY Change	31.42%	-25.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$45.89M	-$37.93M
YoY Change	20.99%
Common Stock	$45.41M	$43.29M
YoY Change	4.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$42.74K	$5.432M
YoY Change
Total Liabilities & Shareholders Equity	$6.180M	$10.17M
YoY Change	-39.22%	-64.97%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$1.463M	-$1.222M
YoY Change	19.67%	36.11%
Depreciation, Depletion And Amortization	$13.52K	$18.42K
YoY Change	-26.62%	-15.75%
Cash From Operating Activities	-$221.7K	-$732.4K
YoY Change	-69.73%	-14.5%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$200.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-$221.7K	-$732.4K
Cash From Investing Activities
Cash From Financing Activities	$200.0K
Net Change In Cash	-$96.04K	-$724.8K
YoY Change	-86.75%
FREE CASH FLOW
Cash From Operating Activities	-$221.7K	-$732.4K
Capital Expenditures		$0.00
Free Cash Flow		-$732.4K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Trading Symbol TradingSymbol	NVFY
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost		usd
CY2023Q1	NVFY	Increase Decrease In Advance From Customers IncreaseDecreaseInAdvanceFromCustomers		usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2024Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2426147	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273100	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	135891	usd
CY2024Q1	NVFY	Advance To Suppliers AdvanceToSuppliers	49458	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2512758	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	898623	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24175	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3894005	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267300	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1723549	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7132	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	69238	usd
CY2024Q1	us-gaap	Goodwill Goodwill	218606	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	2285825	usd
CY2024Q1	us-gaap	Assets Assets	6179830	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	572194	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	686090	usd
CY2024Q1	NVFY	Advance From Customers Current AdvanceFromCustomersCurrent	453975	usd
CY2024Q1	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	201863	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1291380	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1129851	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4335353	usd
CY2024Q1	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	146608	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1097500	usd
CY2024Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	643112	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1887220	usd
CY2024Q1	us-gaap	Liabilities Liabilities	6222573	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2345179	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2345179	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1917706	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1917706	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2345	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45407744	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	439734	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45892566	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-42743	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6179830	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2376393	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1360233	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1213263	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	1016160	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	661302	usd
CY2024Q1	us-gaap	Selling Expense SellingExpense	559470	usd
CY2023Q1	us-gaap	Selling Expense SellingExpense	714514	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1193865	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1130280	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	751216	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2504551	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1844912	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1488391	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1183610	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1581	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1719	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	73032	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5383	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3942	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1909	usd
CY2024Q1	NVFY	Financial Expenses FinancialExpenses	45036	usd
CY2023Q1	NVFY	Financial Expenses FinancialExpenses	33132	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25635	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38705	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1462756	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1222315	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1462756	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1222315	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-81691	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3107	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1544447	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1225422	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2236514	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2236514	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1434012	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1434012	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	496354	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3226	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	222125	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	30000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	750000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-81691	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1462756	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-42743	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6611830	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6611830	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	885	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	16000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	28718	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3107	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1222315	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5432011	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5432011	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1462756	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1222315	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14857	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19759	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	178753	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	193941	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	38982	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	85672	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	251948	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	46885	usd
CY2024Q1	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	750000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	841	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-261	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	89734	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26098	usd
CY2024Q1	NVFY	Increase Decrease In Advance To Suppliers IncreaseDecreaseInAdvanceToSuppliers	-44282	usd
CY2023Q1	NVFY	Increase Decrease In Advance To Suppliers IncreaseDecreaseInAdvanceToSuppliers	41707	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	338429	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-677033	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-86130	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	331233	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-178605	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-196838	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	142149	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	94923	usd
CY2024Q1	NVFY	Increase Decrease In Advance From Customers IncreaseDecreaseInAdvanceFromCustomers	150517	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	189363	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	15806	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-100184	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-221702	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-732421	usd
CY2024Q1	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	200000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-74335	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7654	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-96037	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-724767	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	369137	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1374167	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	273100	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	649400	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	197488	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	5193	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1951	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1460000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1220000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45890000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44430000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	270000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	370000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-5
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zekzDaezsBhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zEdKYaszapI3">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the dates of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to, revenue recognition, the allowance for expected credit losses, valuation of inventories, the valuation of stock-based compensation, income taxes and unrecognized tax benefits, valuation allowance for deferred tax assets, assumptions used in assessing impairment of long-lived assets and goodwill, and loss contingencies. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash And Due From Banks CashAndDueFromBanks	0	usd
CY2023Q4	us-gaap	Cash And Due From Banks CashAndDueFromBanks	0	usd
CY2024Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	137264	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	47530	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1373	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	532	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	135891	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	46998	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	841	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-261	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q1	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	25300000	usd
CY2023Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	25400000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1462756	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1222315	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2236514	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2236514	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1434012	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1434012	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	0	shares
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z9iEzZmIPTze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zPMFakO7yNge">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to credit risk consist primarily of accounts <span style="background-color: white">receivable </span> and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zVmE6dvUVc4" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zGf2iFo0YmD8" title="Concentration risk percentage">10</span></span>% or more of the Company’s sales for the three months ended March 31, 202<span style="background-color: white">4</span> and 202<span style="background-color: white">3</span>. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One customer accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z8WOSlT5y4n9">81</span>% of the Company’s gross accounts receivable as of March 31, 2024. Three customers accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zlsdNFi8mXSc">26</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zd5WYM0ZoRP9">23</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zES3eZUWYgW">19</span>% of the Company’s gross accounts receivable as of December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchased its products from <span style="background-color: white">two and </span> three major vendors during the three months ended March 31, 202<span style="background-color: white">4</span> and 2023, respectively, accounting for a total of <span style="background-color: white"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeMajorVendorsMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zZjAgvr8K2H">20</span>% (<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zKT0ox5TtqJa">10</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zyCzvKOVva">10</span>%) for the three months ended March 31, 2024 and</span> <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeMajorVendorsMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zLnO11tJwPXi">68</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% (<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zYSjhsJc3yf9">35</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z3x2aWASsHMd">19</span><span style="background-color: white">% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zZR6Kbl5TeRk">14</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%) for the three months ended March 31, 2023 of the Company’s purchases from continuing operations, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances made to these major vendors were $<span id="xdx_908_ecustom--AdvancesToSuppliers_iI_c20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zNeoIz4hUpAb" title="Advances made to suppliers">12,532</span> and $<span id="xdx_90E_ecustom--AdvancesToSuppliers_iI_c20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z12AZwWZOTN9" title="Advances made to suppliers">0</span> as of March 31, 2024 and December 31, 2023, respectively. Accounts payable to these major vendors were $<span id="xdx_90B_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zDHnkQwXj5Wk">178,192 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zgPHLgRYYkua">266,652 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of March 31, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z6HiNKlhN26d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zctYM3gHAzB5">Reclassification</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period accounts have been reclassified in conformity with current period’s presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Inventory Net InventoryNet	2512758	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2213311	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	622550	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	633589	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	355250	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	345916	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267300	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	287673	usd
CY2024Q1	us-gaap	Depreciation Depreciation	13516	usd
CY2023Q1	us-gaap	Depreciation Depreciation	18418	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19668	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18327	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7132	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8473	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1341	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1341	usd
CY2024Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	49458	usd
CY2023Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	93740	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	898623	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	984934	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24175	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	41265	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	922798	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1026199	usd
CY2024Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1061338	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	139722	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6804	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7511	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	69337	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	85000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	29745	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	27545	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	71116	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	58669	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	37377	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	672877	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1291380	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1100661	usd
CY2023	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	675000	usd
CY2024Q1	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	750000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13400	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.55
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P0Y9M25D
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	13400	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	14.55
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P0Y9M25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13400	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.55
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P0Y6M25D
CY2024Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	13400	shares
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	14.55
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P0Y6M25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	2.99
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2376393	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1874565	usd
CY2024Q1	us-gaap	Noncurrent Assets NoncurrentAssets	2060087	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	2192021	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	194441	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	219685	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	558870	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	701142	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	598820	usd
CY2024Q1	NVFY	Lessee Operating Lease Liability Payments Due After Year Two LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1858832	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75242	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1783590	usd
CY2024Q1	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	178605	usd
CY2023Q1	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	215193	usd
CY2023Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	750000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-019874-index-headers.html	Edgar Link	pending
0001493152-24-019874-index.html	Edgar Link	pending
0001493152-24-019874.txt	Edgar Link	pending
0001493152-24-019874-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvfy-20240331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nvfy-20240331_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
nvfy-20240331_lab.xml	Edgar Link	unprocessable
nvfy-20240331_pre.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nvfy-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVFY
Nova Lifestyle, Inc. Stock $nvfy

2024 Q1 Form 10-Q Financial Statement

#000149315224019874 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVFY Nova Lifestyle, Inc. Stock $nvfy

2024 Q1 Form 10-Q Financial Statement

#000149315224019874 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVFY
Nova Lifestyle, Inc. Stock $nvfy